MedTrace Logo

Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome

NCT02295202 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-18

No results posted yet for this study

Summary

Obstructive Sleep Apnea (OSA) is a common condition that may induce hemodynamic and metabolic dysregulation. However, it is not clear if OSA is a mere epiphenomenon or contributes to increase the morbidity associated with metabolic syndrome. This study was designed to evaluate the impact of OSA treatment with CPAP in consecutive patients with metabolic syndrome.

Conditions

Interventions

DEVICE

CPAP (REMstar System One Plus - Philips Medical Systems)

Standard device for treating obstructive sleep apnea.

DEVICE

Nasal strips

Sponsors & Collaborators

  • Fleury

    collaborator UNKNOWN

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Luciano F Drager, MD, PhD · Heart Institute (InCor), University of Sao Paulo Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2019-04-30
Completion
2019-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02295202 on ClinicalTrials.gov